Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients

Luca Laurenti, Patrizia Chiusolo, Federica Sora', Simona Sica, Michele Palladino, Paola Piccioni, Idanna Innocenti, Michela Tarnani, Giuseppe Leone

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Few data are available to date on the dose of oral valganciclovir as cytomegalovirus (CMV) preemptive therapy in stem cell transplantation patients. This study aimed to evaluate the efficacy and safety of low-dose valganciclovir (900 mg/day) as preemptive treatment in allotransplanted recipients. Valganciclovir was used in 34 patients who underwent allogeneic stem cell transplantation for hematological malignancies at the dose of 900 mg oral administration/day (12 patients, group 1) or 1,800 mg oral administration/day (22 patients, group 2). Thirty-two out of 34 patients (94%) obtained negativization of polymerase chain reaction for CMV at a median of 12.5 days from the beginning of valganciclovir administration (10/12 patients of group 1, 22/22 patients of group 2). We conclude that oral administration of valganciclovir can induce clearance of CMV viral load in about 2 weeks; moreover, lower-dose oral valganciclovir (900 mg/day) has a comparable efficacy to the proposed standard dose (1,800 mg/day).
Original languageEnglish
Pages (from-to)230-234
Number of pages5
JournalActa Haematologica
Volume123
DOIs
Publication statusPublished - 2010

Keywords

  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents
  • Cytomegalovirus
  • Cytomegalovirus Infections
  • Female
  • Ganciclovir
  • Hematologic Neoplasms
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Transplantation, Homologous
  • Viral Load

Fingerprint

Dive into the research topics of 'Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients'. Together they form a unique fingerprint.

Cite this